Simopoulos, AP. Importance of the ratio of omega-6/omega-3 essential fatty acids: evolutionary aspects. World Rev Nutr Diet. 2003;92, 1–22.
Naughton, SS, Mathai, ML, Hryciw, DH, McAinch, AJ. Linoleic acid and the pathogenesis of obesity. Prostaglandins Other Lipid Mediat. 2016;125, 90–99.
Shrestha, N, Cuffe, JSM, Holland, OJ, et al. Elevated maternal linoleic acid reduces circulating leptin concentrations, cholesterol levels and male fetal survival in a rat model. J Physiol. 2019;597, 3349–3361.
Shrestha, N, Cuffe, JSM, Holland, OJ, Perkins, AV, McAinch, AJ, Hryciw, DH. Linoleic acid increases prostaglandin E2 release and reduces mitochondrial respiration and cell viability in human trophoblast-like cells. Cell Physiol Biochem. 2019;52, 94–108.
Lafond, J, Simoneau, L, Savard, R, Gagnon, MC. Linoleic acid transport by human placental syncytiotrophoblast membranes. Eur J Biochem. 1994;226, 707–713.
Woods, L, Perez-Garcia, V, Hemberger, M. Regulation of placental development and its impact on fetal growth-new insights from mouse models. Front Endocrinol. 2018;9, 570.
Simopoulos, AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother. 2002;56, 365–379.
Abdelmagid, SA, Clarke, SE, Nielsen, DE, et al. Comprehensive profiling of plasma fatty acid concentrations in young healthy Canadian adults. PLoS One. 2015;10, e0116195.
Courville, AB, Keplinger, MR, Judge, MP, Lammi-Keefe, CJ. Plasma or red blood cell phospholipids can be used to assess docosahexaenoic acid status in women during pregnancy. Nutr Res. 2009;29, 151–155.
Vidakovic, AJ, Jaddoe, VW, Voortman, T, Demmelmair, H, Koletzko, B, Gaillard, R. Maternal plasma polyunsaturated fatty acid levels during pregnancy and childhood lipid and insulin levels. Nutr Metab Cardiovasc Dis. 2017;27, 78–85.
Sakayori, N, Kikkawa, T, Tokuda, H, et al. Maternal dietary imbalance between omega-6 and omega-3 polyunsaturated fatty acids impairs neocortical development via epoxy metabolites. Stem Cells. 2016;34, 470–482.
Fride, E, Gobshtis, N, Dahan, H, Weller, A, Giuffrida, A, Ben-Shabat, S. The endocannabinoid system during development: emphasis on perinatal events and delayed effects. Vitam Horm. 2009;81, 139–158.
Pertwee, RG. Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol. 2008;13, 147–159.
Jenkin, KA, Verty, AN, McAinch, AJ, Hryciw, DH. Endocannabinoids and the renal proximal tubule: an emerging role in diabetic nephropathy. Int J Biochem Cell Biol. 2012;44, 2028–2031.
O’Sullivan, SE, Kendall, PJ, Kendall, DA. Endocannabinoids and the cardiovascular response to stress. J Psychopharmacol. 2012;26, 71–82.
Duerr, GD, Heinemann, JC, Suchan, G et al. The endocannabinoid-CB2 receptor axis protects the ischemic heart at the early stage of cardiomyopathy. Basic Res Cardiol. 2014; 109, 425.
Bukiya, AN. Physiology of the endocannabinoid system during development. Adv Exp Med Biol. 2019;1162, 13–37.
Briffa, JF, McAinch, AJ, Romano, T, Wlodek, ME, Hryciw, DH. Leptin in pregnancy and development: a contributor to adulthood disease? Am J Physiol Endocrinol Metab. 2015;308, E335–E350.
Ramirez-Orozco, RE, Garcia-Ruiz, R, Morales, P, Villalon, CM, Villafan-Bernal, JR, Marichal-Cancino, BA. Potential metabolic and behavioural roles of the putative endocannabinoid receptors GPR18, GPR55 and GPR119 in feeding. Curr Neuropharmacol. 2019; 17, 947–960.
Dainese, E, De Fabritiis, G, Sabatucci, A, et al. Membrane lipids are key modulators of the endocannabinoid-hydrolase FAAH. Biochem J. 2014;457, 463–472.
Pacher, P, Steffens, S. The emerging role of the endocannabinoid system in cardiovascular disease. Semin Immunopathol. 2009;31, 63–77.
Nagarkatti, P, Pandey, R, Rieder, SA, Hegde, VL, Nagarkatti, M. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 2009;1, 1333–1349.
Shrestha, N, Cuffe, JSM, Hutchinson, DS, et al. Peripheral modulation of the endocannabinoid system in metabolic disease. Drug Discov Today. 2018;23, 592–604.
Bustin, SA, Benes, V, Garson, JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55, 611–622.
Watkins, SJ, Borthwick, GM, Arthur, HM. The H9C2 cell line and primary neonatal cardiomyocyte cells show similar hypertrophic responses in vitro. In Vitro Cell Dev Biol Anim. 2011;47, 125–131.
Cetrullo, S, Tantini, B, Flamigni, F, et al. Antiapoptotic and antiautophagic effects of eicosapentaenoic acid in cardiac myoblasts exposed to palmitic acid. Nutrients. 2012;4, 78–90.
Siegmund, SV, Seki, E, Osawa, Y, Uchinami, H, Cravatt, BF, Schwabe, RF. Fatty acid amide hydrolase determines anandamide-induced cell death in the liver. J Biol Chem. 2006;281, 10431–10438.
Maia, J, Almada, M, Silva, A, et al. The endocannabinoid system expression in the female reproductive tract is modulated by estrogen. J Steroid Biochem Mol Biol. 2017;174, 40–47.
Sun, HJ, Lu, Y, Wang, HW, et al. Activation of endocannabinoid receptor 2 as a mechanism of propofol pretreatment-induced cardioprotection against ischemia-reperfusion injury in rats. Oxid Med Cell Longev. 2017;2017, 2186383.
Defer, N, Wan, J, Souktani, R, et al. The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy. FASEB J. 2009;23, 2120–2130.